How will state exchanges handle cancer drugs?
More like this
- A Conversation With F. Randy Vogenberg, PhD, RPh: Changing Market for Pharmacy Benefits
- Do the Numbers Add Up for Oral Oncology Quantity-Limit Programs?
- Rebates for Anti-Anemia Drugs Draw Response From FDA, CMS
- Free Statins Disrupt Pharmacy Benefit Plans
- Health Care Reform Injects Economics Into the Biologics 'Value Equation'